Cortexyme, Inc. (NASDAQ:CRTX – Get Free Report) shares crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $1.37 and traded as high as $1.56. Cortexyme shares last traded at $1.54, with a volume of 48,558 shares.
Cortexyme Trading Up 0.7 %
The firm has a 50-day moving average of $1.61 and a two-hundred day moving average of $1.38. The firm has a market capitalization of $45.53 million, a P/E ratio of -0.51 and a beta of 1.40.
About Cortexyme
Cortexyme, Inc, a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's and other degenerative diseases. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease, as well as for the treatment of oral squamous cell carcinoma, periodontitis, and coronavirus infection.
Further Reading
- Five stocks we like better than Cortexyme
- What Are Some of the Best Large-Cap Stocks to Buy?
- These 4 Tech ETFs Just Hit 50-Day Lows—Time to Buy?
- How to Invest in Biotech Stocks
- 3 Stocks to Buy While Others Stay on the Sidelines
- What is a Low P/E Ratio and What Does it Tell Investors?
- MarketBeat Week in Review – 03/03 – 03/07
Receive News & Ratings for Cortexyme Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cortexyme and related companies with MarketBeat.com's FREE daily email newsletter.
